“We’ve known for decades now that this is a liver disorder that already starts causing liver damage…in utero,” Musunuru says. Usually, this condition is treated with medication after birth, beginning as soon as it is detected. HT1 can cause liver cancer or even liver failure, along with a host of other symptoms. But in the mice, their new treatment impacts the disease earlier and only needs to be administered once–as opposed to the current (human) medication, which must be taken every day. Unlike the medication treatment, the gene editing treatment also means that a special low-protein diet isn’t needed.